CTI Clinical Trial and Consulting Services Collaborated with Tuberous Sclerosis Alliance to Analyze Natural History Database

CINCINNATI--()--CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization announces it recently collaborated with the Tuberous Sclerosis Alliance to analyze a Natural History Database of currently more than 1,700 people with tuberous sclerosis complex (TSC).

In 2006, the Tuberous Sclerosis Alliance, in partnership with a network of TSC Clinics, launched the TSC Natural History Database, the first-of-its-kind project to collect information about TSC, which affects various organs in the human body including the brain, heart, kidneys, lungs, liver, skin and eyes. TSC is also associated with developmental disorders such as autism.

The analysis, performed by CTI and the Tuberous Sclerosis Alliance, was designed to compare various manifestations between genotypes and to determine if correlations exist between TSC symptoms and the TSC gene mutation. Data will be presented comparing various characteristics between TSC1 and TSC2 genotypes at the International TSC Research Conference.

“We’re finding that groups like the Tuberous Sclerosis Alliance are becoming increasingly more important in drug development and research in rare diseases, as there is often a lack of information on rare disorders in published literature or traditional databases,” according to Joseph McCafferty, Vice President, North American Sales. “CTI is at the forefront in advancing these kind of collaborations and research efforts, and we’re pleased to assist the Tuberous Sclerosis Alliance advance their mission to find a cure for TSC.”

“We are extremely proud to partner with CTI presenting this important analysis of data from the TSC Natural History Database. For individuals and families who have participated in this study, we are hopeful this type of information will help lead to scientific breakthroughs, ultimately improving the quality of life for those struggling with the daily challenges of TSC,” shared Kari Luther Rosbeck, President and CEO of the Tuberous Sclerosis Alliance.

About CTI Clinical Trial and Consulting Services

CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. CTI is headquartered in Cincinnati, OH with operations around the world. www.ctifacts.com

About Tuberous Sclerosis Alliance

The Tuberous Sclerosis Alliance is the only national voluntary health organization in the US dedicated to finding a cure for tuberous sclerosis complex (TSC) while improving the lives of those affected. TSC is a rare genetic disorder that causes tumors to form in vital organs. TSC affects about 50,000 in the US and over 1 million worldwide. Currently, there is no cure. Since 2010, there have been two FDA-approved treatments to shrink tumors in the brain and kidneys of those with TSC, and promising research continues for additional therapies to improve the quality of daily life for every individual with TSC. www.tsalliance.org

Contacts

CTI Clinical Trial and Consulting Services
Allison Schroeder, 513-598-9290
aschroeder@ctifacts.com

Release Summary

CTI announces it recently collaborated with the Tuberous Sclerosis Alliance to analyze a Natural History Database of more than 1,700 people with tuberous sclerosis complex (TSC).

Contacts

CTI Clinical Trial and Consulting Services
Allison Schroeder, 513-598-9290
aschroeder@ctifacts.com